Concepts (267)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 33 | 2018 | 1328 | 1.730 |
Why?
|
| Dobutamine | 15 | 2018 | 69 | 1.170 |
Why?
|
| Ventricular Function, Left | 17 | 2016 | 245 | 1.150 |
Why?
|
| Magnetic Resonance Imaging, Cine | 10 | 2016 | 103 | 0.820 |
Why?
|
| Ventricular Dysfunction, Left | 10 | 2016 | 170 | 0.810 |
Why?
|
| Anthracyclines | 6 | 2016 | 62 | 0.680 |
Why?
|
| Myocardial Contraction | 6 | 2015 | 63 | 0.670 |
Why?
|
| Stroke Volume | 11 | 2016 | 348 | 0.580 |
Why?
|
| Exercise Test | 9 | 2015 | 227 | 0.500 |
Why?
|
| Cardiotonic Agents | 7 | 2015 | 48 | 0.480 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2016 | 74 | 0.440 |
Why?
|
| Myocardial Ischemia | 5 | 2018 | 107 | 0.430 |
Why?
|
| Coronary Vessels | 3 | 2010 | 165 | 0.410 |
Why?
|
| Models, Cardiovascular | 2 | 2010 | 32 | 0.410 |
Why?
|
| Music Therapy | 2 | 2008 | 7 | 0.400 |
Why?
|
| Heart Failure | 9 | 2015 | 639 | 0.400 |
Why?
|
| Predictive Value of Tests | 17 | 2018 | 876 | 0.380 |
Why?
|
| Middle Aged | 42 | 2018 | 11839 | 0.370 |
Why?
|
| Myocardial Perfusion Imaging | 3 | 2016 | 27 | 0.370 |
Why?
|
| Image Enhancement | 1 | 2010 | 72 | 0.350 |
Why?
|
| Aged | 34 | 2020 | 10314 | 0.340 |
Why?
|
| Heart Ventricles | 4 | 2016 | 135 | 0.330 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2016 | 226 | 0.330 |
Why?
|
| Infant Care | 1 | 2008 | 2 | 0.330 |
Why?
|
| Humans | 55 | 2020 | 32114 | 0.320 |
Why?
|
| Infant, Premature | 1 | 2008 | 69 | 0.320 |
Why?
|
| Chest Pain | 4 | 2011 | 208 | 0.310 |
Why?
|
| Female | 45 | 2018 | 20015 | 0.310 |
Why?
|
| Weight Gain | 1 | 2008 | 117 | 0.300 |
Why?
|
| Emergency Service, Hospital | 4 | 2013 | 474 | 0.300 |
Why?
|
| Male | 43 | 2018 | 19217 | 0.300 |
Why?
|
| Myocardial Infarction | 8 | 2015 | 475 | 0.300 |
Why?
|
| Cardiovascular Diseases | 5 | 2014 | 1128 | 0.290 |
Why?
|
| Risk Factors | 18 | 2018 | 3880 | 0.270 |
Why?
|
| Echocardiography, Stress | 4 | 2016 | 27 | 0.250 |
Why?
|
| Myocardium | 6 | 2016 | 186 | 0.250 |
Why?
|
| Ventricular Remodeling | 3 | 2016 | 58 | 0.240 |
Why?
|
| Prospective Studies | 14 | 2020 | 2283 | 0.240 |
Why?
|
| Heart Diseases | 4 | 2011 | 116 | 0.230 |
Why?
|
| Aged, 80 and over | 16 | 2018 | 3990 | 0.230 |
Why?
|
| Coronary Circulation | 3 | 2016 | 43 | 0.220 |
Why?
|
| Time Factors | 12 | 2018 | 2151 | 0.220 |
Why?
|
| Cardiomyopathies | 2 | 2016 | 56 | 0.220 |
Why?
|
| Contrast Media | 6 | 2015 | 138 | 0.220 |
Why?
|
| Aging | 5 | 2020 | 946 | 0.210 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2013 | 58 | 0.210 |
Why?
|
| Heptanoic Acids | 2 | 2014 | 29 | 0.210 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2016 | 120 | 0.210 |
Why?
|
| Pyrroles | 2 | 2014 | 55 | 0.200 |
Why?
|
| Blood Flow Velocity | 4 | 2011 | 77 | 0.200 |
Why?
|
| Acute Coronary Syndrome | 3 | 2013 | 196 | 0.200 |
Why?
|
| Prognosis | 10 | 2018 | 1497 | 0.190 |
Why?
|
| Organometallic Compounds | 3 | 2010 | 23 | 0.190 |
Why?
|
| Adult | 19 | 2020 | 9380 | 0.190 |
Why?
|
| Leukemia | 2 | 2013 | 40 | 0.180 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 608 | 0.180 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2020 | 109 | 0.170 |
Why?
|
| Edema, Cardiac | 2 | 2016 | 13 | 0.170 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2014 | 77 | 0.160 |
Why?
|
| Vasodilator Agents | 3 | 2014 | 62 | 0.150 |
Why?
|
| Risk Assessment | 9 | 2018 | 1429 | 0.150 |
Why?
|
| Aorta | 3 | 2009 | 126 | 0.150 |
Why?
|
| Muscle, Skeletal | 2 | 2020 | 519 | 0.150 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 765 | 0.140 |
Why?
|
| Aortic Diseases | 2 | 2011 | 63 | 0.140 |
Why?
|
| Sex Factors | 2 | 2016 | 667 | 0.140 |
Why?
|
| Severity of Illness Index | 4 | 2015 | 881 | 0.140 |
Why?
|
| Adiposity | 2 | 2016 | 198 | 0.140 |
Why?
|
| Phantoms, Imaging | 2 | 2010 | 60 | 0.140 |
Why?
|
| Age Factors | 6 | 2018 | 1189 | 0.130 |
Why?
|
| Reproducibility of Results | 7 | 2015 | 765 | 0.130 |
Why?
|
| Patient Positioning | 1 | 2015 | 23 | 0.130 |
Why?
|
| Stress, Physiological | 2 | 2016 | 55 | 0.130 |
Why?
|
| Exercise Tolerance | 2 | 2009 | 125 | 0.130 |
Why?
|
| Intra-Abdominal Fat | 2 | 2016 | 63 | 0.130 |
Why?
|
| Simvastatin | 1 | 2014 | 25 | 0.120 |
Why?
|
| Survivors | 1 | 2016 | 163 | 0.120 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 10 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 35 | 0.120 |
Why?
|
| Heart Rate | 4 | 2011 | 335 | 0.120 |
Why?
|
| Renal Circulation | 1 | 2014 | 13 | 0.120 |
Why?
|
| Prediabetic State | 1 | 2015 | 65 | 0.120 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2014 | 12 | 0.120 |
Why?
|
| Furosemide | 1 | 2014 | 9 | 0.120 |
Why?
|
| North Carolina | 6 | 2015 | 1538 | 0.120 |
Why?
|
| Renal Artery | 1 | 2014 | 47 | 0.110 |
Why?
|
| Renal Artery Obstruction | 1 | 2014 | 41 | 0.110 |
Why?
|
| Manometry | 1 | 2013 | 19 | 0.110 |
Why?
|
| Polysomnography | 1 | 2013 | 40 | 0.110 |
Why?
|
| Aorta, Thoracic | 2 | 2011 | 85 | 0.110 |
Why?
|
| Coronary Artery Disease | 2 | 2015 | 401 | 0.110 |
Why?
|
| Angina Pectoris | 1 | 2013 | 22 | 0.110 |
Why?
|
| Cardiology Service, Hospital | 1 | 2013 | 23 | 0.110 |
Why?
|
| Oxygen | 1 | 2014 | 142 | 0.110 |
Why?
|
| Disability Evaluation | 1 | 2014 | 240 | 0.110 |
Why?
|
| Lymphoma | 1 | 2013 | 35 | 0.110 |
Why?
|
| Heterocyclic Compounds | 2 | 2010 | 12 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 145 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 246 | 0.100 |
Why?
|
| Cardiac Output | 2 | 2009 | 36 | 0.100 |
Why?
|
| Adenoidectomy | 1 | 2012 | 3 | 0.100 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2012 | 3 | 0.100 |
Why?
|
| Tonsillectomy | 1 | 2012 | 11 | 0.100 |
Why?
|
| Esophageal pH Monitoring | 1 | 2012 | 4 | 0.100 |
Why?
|
| Sodium Chloride | 1 | 2012 | 22 | 0.100 |
Why?
|
| Rhinitis | 1 | 2012 | 11 | 0.100 |
Why?
|
| Sinusitis | 1 | 2012 | 17 | 0.100 |
Why?
|
| Atrial Function, Left | 1 | 2012 | 18 | 0.100 |
Why?
|
| Ventricular Function, Right | 1 | 2011 | 17 | 0.100 |
Why?
|
| Arteries | 2 | 2013 | 67 | 0.100 |
Why?
|
| Hospital Costs | 1 | 2011 | 38 | 0.100 |
Why?
|
| Pulmonary Edema | 1 | 2011 | 11 | 0.100 |
Why?
|
| Health Expenditures | 1 | 2011 | 66 | 0.090 |
Why?
|
| Perfusion Imaging | 1 | 2011 | 8 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 99 | 0.090 |
Why?
|
| Patient Admission | 1 | 2011 | 60 | 0.090 |
Why?
|
| Inpatients | 1 | 2011 | 85 | 0.090 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2010 | 12 | 0.090 |
Why?
|
| Pulsatile Flow | 1 | 2010 | 26 | 0.090 |
Why?
|
| Abdominal Fat | 1 | 2010 | 50 | 0.090 |
Why?
|
| Cerebrovascular Circulation | 1 | 2011 | 93 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2014 | 3306 | 0.090 |
Why?
|
| Coronary Stenosis | 2 | 2016 | 30 | 0.090 |
Why?
|
| Doxorubicin | 1 | 2010 | 82 | 0.090 |
Why?
|
| Bicycling | 1 | 2009 | 14 | 0.090 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2009 | 30 | 0.080 |
Why?
|
| Delivery of Health Care | 1 | 2011 | 161 | 0.080 |
Why?
|
| Meglumine | 1 | 2009 | 4 | 0.080 |
Why?
|
| Gadolinium DTPA | 1 | 2009 | 16 | 0.080 |
Why?
|
| Computer Simulation | 1 | 2010 | 220 | 0.080 |
Why?
|
| Women's Health Services | 1 | 2009 | 11 | 0.080 |
Why?
|
| Atropine | 4 | 2011 | 22 | 0.080 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 582 | 0.080 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2010 | 140 | 0.080 |
Why?
|
| Sucking Behavior | 1 | 2008 | 4 | 0.080 |
Why?
|
| Therapeutic Touch | 1 | 2009 | 10 | 0.080 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2008 | 10 | 0.080 |
Why?
|
| Infant Behavior | 1 | 2008 | 9 | 0.080 |
Why?
|
| Single-Blind Method | 3 | 2020 | 203 | 0.080 |
Why?
|
| Endothelium, Vascular | 2 | 2016 | 156 | 0.080 |
Why?
|
| Lower Extremity | 1 | 2009 | 100 | 0.080 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2010 | 199 | 0.080 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2009 | 44 | 0.080 |
Why?
|
| Proportional Hazards Models | 4 | 2013 | 753 | 0.080 |
Why?
|
| Outpatients | 1 | 2008 | 57 | 0.080 |
Why?
|
| Angina, Unstable | 3 | 2015 | 21 | 0.070 |
Why?
|
| Adipose Tissue | 1 | 2010 | 349 | 0.070 |
Why?
|
| Heart Valve Diseases | 1 | 2007 | 27 | 0.070 |
Why?
|
| Heart Defects, Congenital | 1 | 2007 | 31 | 0.070 |
Why?
|
| Leg | 1 | 2006 | 65 | 0.070 |
Why?
|
| Infant, Newborn | 1 | 2008 | 672 | 0.070 |
Why?
|
| Kidney | 1 | 2010 | 518 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 2008 | 221 | 0.070 |
Why?
|
| Fibrosis | 2 | 2016 | 120 | 0.070 |
Why?
|
| Hospitalization | 3 | 2018 | 470 | 0.070 |
Why?
|
| Linear Models | 3 | 2012 | 449 | 0.070 |
Why?
|
| Costs and Cost Analysis | 2 | 2020 | 100 | 0.070 |
Why?
|
| Disease Progression | 2 | 2018 | 594 | 0.060 |
Why?
|
| Electrocardiography | 4 | 2013 | 605 | 0.060 |
Why?
|
| Observer Variation | 3 | 2012 | 105 | 0.060 |
Why?
|
| Echocardiography | 3 | 2011 | 159 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2016 | 1542 | 0.060 |
Why?
|
| Hypertension | 1 | 2010 | 960 | 0.050 |
Why?
|
| Child | 4 | 2012 | 2442 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2009 | 898 | 0.050 |
Why?
|
| Intraoperative Complications | 1 | 2002 | 56 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2015 | 464 | 0.050 |
Why?
|
| Length of Stay | 2 | 2013 | 314 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 770 | 0.050 |
Why?
|
| Exercise | 1 | 2006 | 673 | 0.050 |
Why?
|
| Poisson Distribution | 1 | 2020 | 17 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 297 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2020 | 93 | 0.040 |
Why?
|
| Education, Distance | 1 | 2020 | 19 | 0.040 |
Why?
|
| Myosin Heavy Chains | 1 | 2020 | 89 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2012 | 525 | 0.040 |
Why?
|
| Oxygen Consumption | 2 | 2015 | 154 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2011 | 2265 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2012 | 100 | 0.040 |
Why?
|
| Regional Blood Flow | 2 | 2009 | 86 | 0.040 |
Why?
|
| Gadolinium | 2 | 2010 | 22 | 0.040 |
Why?
|
| Adenosine | 2 | 2011 | 59 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 2016 | 33 | 0.030 |
Why?
|
| Femoral Artery | 2 | 2009 | 50 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2009 | 108 | 0.030 |
Why?
|
| Microcirculation | 1 | 2016 | 65 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2015 | 3510 | 0.030 |
Why?
|
| Young Adult | 2 | 2013 | 2665 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 684 | 0.030 |
Why?
|
| Comorbidity | 1 | 2016 | 566 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 245 | 0.030 |
Why?
|
| Infant | 2 | 2008 | 1062 | 0.030 |
Why?
|
| Vasodilation | 2 | 2006 | 94 | 0.030 |
Why?
|
| Brachial Artery | 1 | 2014 | 69 | 0.030 |
Why?
|
| Equipment Safety | 1 | 2013 | 20 | 0.030 |
Why?
|
| Systole | 2 | 2005 | 99 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 187 | 0.030 |
Why?
|
| Troponin I | 1 | 2013 | 22 | 0.030 |
Why?
|
| Observation | 1 | 2013 | 25 | 0.030 |
Why?
|
| Equipment Design | 1 | 2013 | 171 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 276 | 0.030 |
Why?
|
| Myocardial Revascularization | 1 | 2013 | 41 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2013 | 66 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 257 | 0.030 |
Why?
|
| Mobility Limitation | 1 | 2014 | 219 | 0.030 |
Why?
|
| Troponin | 1 | 2013 | 106 | 0.030 |
Why?
|
| Gastric Acidity Determination | 1 | 2012 | 4 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2015 | 494 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2012 | 31 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2011 | 26 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2013 | 126 | 0.030 |
Why?
|
| Laryngoscopy | 1 | 2012 | 41 | 0.020 |
Why?
|
| Survival Rate | 1 | 2014 | 877 | 0.020 |
Why?
|
| Models, Economic | 1 | 2011 | 20 | 0.020 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2011 | 15 | 0.020 |
Why?
|
| Cost Savings | 1 | 2011 | 34 | 0.020 |
Why?
|
| Drug Costs | 1 | 2011 | 47 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 989 | 0.020 |
Why?
|
| Spin Labels | 1 | 2011 | 24 | 0.020 |
Why?
|
| Reference Standards | 1 | 2011 | 32 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2011 | 45 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 1199 | 0.020 |
Why?
|
| Self Administration | 1 | 2012 | 297 | 0.020 |
Why?
|
| Diastole | 1 | 2011 | 96 | 0.020 |
Why?
|
| Acute Disease | 1 | 2011 | 253 | 0.020 |
Why?
|
| Heart | 1 | 2011 | 177 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2010 | 62 | 0.020 |
Why?
|
| Software | 1 | 2011 | 123 | 0.020 |
Why?
|
| Medroxyprogesterone | 1 | 2010 | 14 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2011 | 188 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2010 | 28 | 0.020 |
Why?
|
| Iliac Artery | 1 | 2009 | 49 | 0.020 |
Why?
|
| Adolescent | 2 | 2008 | 3568 | 0.020 |
Why?
|
| Muscle Contraction | 1 | 2009 | 114 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 288 | 0.020 |
Why?
|
| Body Composition | 1 | 2010 | 397 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2012 | 923 | 0.020 |
Why?
|
| Affect | 1 | 2008 | 70 | 0.020 |
Why?
|
| Obesity | 1 | 2016 | 1176 | 0.020 |
Why?
|
| Postmenopause | 1 | 2010 | 430 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2008 | 155 | 0.020 |
Why?
|
| United States | 1 | 2016 | 3976 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 352 | 0.020 |
Why?
|
| Neoplasms | 1 | 2014 | 728 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2009 | 350 | 0.020 |
Why?
|
| Transplants | 1 | 2007 | 23 | 0.020 |
Why?
|
| Quality of Life | 1 | 2013 | 946 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2009 | 548 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 1817 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 919 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 1022 | 0.020 |
Why?
|
| Reference Values | 1 | 2006 | 246 | 0.020 |
Why?
|
| Rats | 1 | 2010 | 1596 | 0.020 |
Why?
|
| Rest | 1 | 2006 | 53 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2008 | 1270 | 0.010 |
Why?
|
| Ergometry | 1 | 2002 | 5 | 0.010 |
Why?
|
| Heart Function Tests | 1 | 2002 | 9 | 0.010 |
Why?
|
| Thigh | 1 | 2003 | 42 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 2003 | 153 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2003 | 294 | 0.010 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2002 | 62 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2006 | 845 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2002 | 317 | 0.010 |
Why?
|
| Radiography | 1 | 2003 | 376 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2002 | 472 | 0.010 |
Why?
|
| Algorithms | 1 | 2003 | 495 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 7542 | 0.010 |
Why?
|